PCIDB

KNApSAcK Metabolite C00001492

Metabolite

KNApSAcK Entry

id C00001492
Name Caffeine
CAS RN 58-08-2
Standard InChI InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3
Standard InChI (Main Layer) InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3

Cluster

Phytochemical cluster No. 12
KCF-S cluster No. 3446

Link

ChEMBL

By standard InChI CHEMBL113
By standard InChI Main Layer CHEMBL113

KEGG

By LinkDB C07481

CTD

By CAS RN D002110

Species

Summary

Plant class

class name count
asterids 15
rosids 7
eudicotyledons 1

Family

family name count
Rubiaceae 9
Theaceae 5
Rutaceae 3
Malvaceae 2
Sapindaceae 2
Loranthaceae 1
Aquifoliaceae 1
Noctuidae 1

List (24)

* NCBI
KNApSAcK organism *ID *family *plant class *kingdom
Camellia irawadiensis 4441 Theaceae asterids Viridiplantae
Camellia kissi 319927 Theaceae asterids Viridiplantae
Camellia sinensis 4442 Theaceae asterids Viridiplantae
Camellia sinensis var. sinensis 542762 Theaceae asterids Viridiplantae
Camellia taliensis 182317 Theaceae asterids Viridiplantae
Citrus limon 2708 Rutaceae rosids Viridiplantae
Citrus maxima 37334 Rutaceae rosids Viridiplantae
Citrus paradisi 37656 Rutaceae rosids Viridiplantae
Coffea arabica 13443 Rubiaceae asterids Viridiplantae
Coffea canephora 49390 Rubiaceae asterids Viridiplantae
Coffea dewevrei 213301 Rubiaceae asterids Viridiplantae
Coffea eugenioides 49369 Rubiaceae asterids Viridiplantae
Coffea kianjavatensis 339904 Rubiaceae asterids Viridiplantae
Coffea liberica 49373 Rubiaceae asterids Viridiplantae
Coffea racemosa 49377 Rubiaceae asterids Viridiplantae
Coffea salvatrix 49380 Rubiaceae asterids Viridiplantae
Coffea spp. 13442 Rubiaceae asterids Viridiplantae
Cola acuminata 93760 Malvaceae rosids Viridiplantae
Ilex paraguayensis 4295 Aquifoliaceae asterids Viridiplantae
Paullinia cupana 392747 Sapindaceae rosids Viridiplantae
Paullinia trifoliata 290983 Sapindaceae rosids Viridiplantae
Scurrula atropurpurea 1146880 Loranthaceae eudicotyledons Viridiplantae
Spodoptera litura 69820 Noctuidae Metazoa
Theobroma cacao 3641 Malvaceae rosids Viridiplantae

Human Protein / Gene in interaction

115 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P11217 Glycogen phosphorylase, muscle form Enzyme CHEMBL113 CHEMBL881513 (1)
1 / 1
P10635 Cytochrome P450 2D6 Cytochrome P450 2D6 CHEMBL113 CHEMBL1909136 (2) CHEMBL2071965 (1)
1 / 0
P42345 Serine/threonine-protein kinase mTOR Enzyme CHEMBL113 CHEMBL1767684 (1)
0 / 0
Q9Y6L6 Solute carrier organic anion transporter family member 1B1 Electrochemical transporter CHEMBL113 CHEMBL2169429 (1)
1 / 0
O94956 Solute carrier organic anion transporter family member 2B1 Unclassified protein CHEMBL113 CHEMBL2169431 (1)
0 / 0
P21728 D(1A) dopamine receptor Dopamine receptor CHEMBL113 CHEMBL1909139 (2)
0 / 0
P27338 Amine oxidase [flavin-containing] B Oxidoreductase CHEMBL113 CHEMBL972369 (1)
0 / 0
P35354 Prostaglandin G/H synthase 2 Oxidoreductase CHEMBL113 CHEMBL1014033 (1) CHEMBL1909131 (2)
0 / 3
Q12809 Potassium voltage-gated channel subfamily H member 2 KCNH, Kv10-12.x (Ether-a-go-go) CHEMBL113 CHEMBL1676103 (1) CHEMBL1909190 (2)
2 / 2
P08246 Neutrophil elastase S1A CHEMBL113 CHEMBL1909195 (2)
2 / 1
P33765 Adenosine receptor A3 Adenosine receptor CHEMBL113 CHEMBL643968 (1) CHEMBL644953 (1)
CHEMBL947110 (1) CHEMBL967546 (1)
CHEMBL1061439 (1) CHEMBL1074287 (1)
CHEMBL1909215 (2) CHEMBL2154397 (1)
0 / 0
P78527 DNA-dependent protein kinase catalytic subunit Atypical serine/threonine protein kinase PIKK subfamily CHEMBL113 CHEMBL1767683 (1)
0 / 0
Q16539 Mitogen-activated protein kinase 14 p38 CHEMBL113 CHEMBL1909201 (2)
0 / 0
P06746 DNA polymerase beta Enzyme CHEMBL113 CHEMBL1614079 (1)
0 / 0
P49146 Neuropeptide Y receptor type 2 Neuropeptide Y receptor CHEMBL113 CHEMBL1909176 (2)
0 / 0
Q9Y2T3 Guanine deaminase Enzyme CHEMBL113 CHEMBL1225633 (1)
0 / 0
P29466 Caspase-1 C14 CHEMBL113 CHEMBL1909193 (2)
0 / 0
P17252 Protein kinase C alpha type Alpha CHEMBL113 CHEMBL1909198 (2)
0 / 0
P27361 Mitogen-activated protein kinase 3 Erk CHEMBL113 CHEMBL1909199 (2)
0 / 0
P14780 Matrix metalloproteinase-9 M10A CHEMBL113 CHEMBL1909197 (2)
2 / 2
Q13315 Serine-protein kinase ATM Atypical serine/threonine protein kinase PIKK subfamily CHEMBL113 CHEMBL1767682 (1)
1 / 4
O15245 Solute carrier family 22 member 1 Drug uniporter CHEMBL113 CHEMBL993349 (1)
0 / 0
P10828 Thyroid hormone receptor beta NR1A2 CHEMBL113 CHEMBL1794561 (1)
3 / 1
P29275 Adenosine receptor A2b Adenosine receptor CHEMBL113 CHEMBL642334 (1) CHEMBL636450 (1)
CHEMBL642110 (1) CHEMBL643968 (1)
CHEMBL848253 (1) CHEMBL948832 (1)
CHEMBL951846 (1) CHEMBL1074285 (1)
CHEMBL1211412 (1) CHEMBL2154933 (1)
0 / 0
P00918 Carbonic anhydrase 2 Lyase CHEMBL113 CHEMBL1909123 (2)
1 / 2
P07550 Beta-2 adrenergic receptor Adrenergic receptor CHEMBL113 CHEMBL1909092 (2)
0 / 1
P21397 Amine oxidase [flavin-containing] A Oxidoreductase CHEMBL113 CHEMBL1909169 (2)
1 / 1
P25021 Histamine H2 receptor Histamine receptor CHEMBL113 CHEMBL1909157 (2)
0 / 0
P35367 Histamine H1 receptor Histamine receptor CHEMBL113 CHEMBL1909156 (2)
0 / 0
Q01959 Sodium-dependent dopamine transporter Dopamine CHEMBL113 CHEMBL1909143 (2)
1 / 0
P08912 Muscarinic acetylcholine receptor M5 Acetylcholine receptor CHEMBL113 CHEMBL1909174 (2)
0 / 0
P18825 Alpha-2C adrenergic receptor Adrenergic receptor CHEMBL113 CHEMBL1909090 (2)
0 / 0
P13945 Beta-3 adrenergic receptor Adrenergic receptor CHEMBL113 CHEMBL1909093 (2)
0 / 0
P02768 Serum albumin Secreted protein CHEMBL113 CHEMBL702885 (1) CHEMBL1000711 (1)
0 / 0
P08183 Multidrug resistance protein 1 drug CHEMBL113 CHEMBL2077670 (1) CHEMBL2076205 (1)
1 / 0
P25024 C-X-C chemokine receptor type 1 CXC chemokine receptor CHEMBL113 CHEMBL1909127 (2)
0 / 0
P06241 Tyrosine-protein kinase Fyn Src CHEMBL113 CHEMBL1909204 (2)
0 / 0
Q08828 Adenylate cyclase type 1 Enzyme CHEMBL113 CHEMBL645307 (1)
0 / 0
Q08209 Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform Ser_Thr CHEMBL113 CHEMBL1909202 (2)
0 / 0
P11712 Cytochrome P450 2C9 Cytochrome P450 2C9 CHEMBL113 CHEMBL1909135 (2) CHEMBL2071963 (1)
0 / 1
P00533 Epidermal growth factor receptor TK tyrosine-protein kinase EGFR subfamily CHEMBL113 CHEMBL1909203 (2)
1 / 11
P14416 D(2) dopamine receptor Dopamine receptor CHEMBL113 CHEMBL1909140 (2)
2 / 0
P23219 Prostaglandin G/H synthase 1 Oxidoreductase CHEMBL113 CHEMBL1909130 (2)
0 / 0
P37288 Vasopressin V1a receptor Vasopressin and oxytocin receptor CHEMBL113 CHEMBL1909120 (2)
0 / 0
P41145 Kappa-type opioid receptor Opioid receptor CHEMBL113 CHEMBL1909181 (2)
0 / 0
Q9Y271 Cysteinyl leukotriene receptor 1 Leukotriene receptor CHEMBL113 CHEMBL1909164 (2)
0 / 0
P29274 Adenosine receptor A2a Adenosine receptor CHEMBL113 CHEMBL639494 (1) CHEMBL642334 (1)
CHEMBL642110 (1) CHEMBL643968 (1)
CHEMBL848253 (1) CHEMBL947107 (1)
CHEMBL967545 (1) CHEMBL1061436 (1)
CHEMBL1803433 (2) CHEMBL1909214 (2)
CHEMBL2154931 (1)
0 / 0
P25929 Neuropeptide Y receptor type 1 Neuropeptide Y receptor CHEMBL113 CHEMBL1909175 (2)
0 / 0
P50052 Type-2 angiotensin II receptor Angiotensin receptor CHEMBL113 CHEMBL1909096 (2)
1 / 1
P17948 Vascular endothelial growth factor receptor 1 Vegfr CHEMBL113 CHEMBL1909118 (2)
0 / 0
P41968 Melanocortin receptor 3 Melanocortin receptor CHEMBL113 CHEMBL1909166 (2)
1 / 0
P11509 Cytochrome P450 2A6 Cytochrome P450 2A6 CHEMBL113 CHEMBL1909133 (2)
0 / 0
O75496 Geminin Unclassified protein CHEMBL113 CHEMBL2114780 (1)
0 / 0
P04035 3-hydroxy-3-methylglutaryl-coenzyme A reductase Oxidoreductase CHEMBL113 CHEMBL1909158 (2)
0 / 0
P08913 Alpha-2A adrenergic receptor Adrenergic receptor CHEMBL113 CHEMBL1909088 (2)
0 / 0
P21917 D(4) dopamine receptor Dopamine receptor CHEMBL113 CHEMBL1909142 (2)
0 / 0
P30988 Calcitonin receptor Calcitonin receptor CHEMBL113 CHEMBL1909101 (2)
0 / 0
P35462 D(3) dopamine receptor Dopamine receptor CHEMBL113 CHEMBL1909141 (2)
1 / 0
P41143 Delta-type opioid receptor Opioid receptor CHEMBL113 CHEMBL1909180 (2)
0 / 0
Q92731 Estrogen receptor beta NR3A2 CHEMBL113 CHEMBL1909146 (2)
0 / 1
P41595 5-hydroxytryptamine receptor 2B Serotonin receptor CHEMBL113 CHEMBL1909104 (2)
0 / 0
P25101 Endothelin-1 receptor Endothelin receptor CHEMBL113 CHEMBL1909144 (2)
0 / 0
P30411 B2 bradykinin receptor Bradykinin receptor CHEMBL113 CHEMBL1909100 (2)
0 / 0
P32245 Melanocortin receptor 4 Melanocortin receptor CHEMBL113 CHEMBL1909167 (2)
1 / 0
P32238 Cholecystokinin receptor type A Cholecystokinin receptor CHEMBL113 CHEMBL1909129 (2)
0 / 0
P08311 Cathepsin G S1A CHEMBL113 CHEMBL1909194 (2)
0 / 0
Q99720 Sigma non-opioid intracellular receptor 1 Membrane receptor CHEMBL113 CHEMBL1909110 (2)
1 / 0
P03956 Interstitial collagenase M10A CHEMBL113 CHEMBL1909196 (2)
0 / 1
Q13535 Serine/threonine-protein kinase ATR Atypical serine/threonine protein kinase PIKK subfamily CHEMBL113 CHEMBL1767585 (1)
2 / 2
P32241 Vasoactive intestinal polypeptide receptor 1 Vasoactive intestinal peptide receptor CHEMBL113 CHEMBL1909119 (2)
0 / 0
P83916 Chromobox protein homolog 1 Unclassified protein CHEMBL113 CHEMBL1738610 (1)
0 / 0
Q9NPD5 Solute carrier organic anion transporter family member 1B3 Electrochemical transporter CHEMBL113 CHEMBL2169430 (1)
1 / 0
P04150 Glucocorticoid receptor NR3C1 CHEMBL113 CHEMBL1794456 (1) CHEMBL1909150 (2)
0 / 1
P08172 Muscarinic acetylcholine receptor M2 Acetylcholine receptor CHEMBL113 CHEMBL1909171 (2)
2 / 0
P11229 Muscarinic acetylcholine receptor M1 Acetylcholine receptor CHEMBL113 CHEMBL1909170 (2)
0 / 0
P21554 Cannabinoid receptor 1 Cannabinoid receptor CHEMBL113 CHEMBL1909122 (2)
0 / 0
P31645 Sodium-dependent serotonin transporter Serotonin CHEMBL113 CHEMBL1909109 (2)
2 / 0
P04626 Receptor tyrosine-protein kinase erbB-2 TK tyrosine-protein kinase EGFR subfamily CHEMBL113 CHEMBL1909205 (2)
5 / 10
P20309 Muscarinic acetylcholine receptor M3 Acetylcholine receptor CHEMBL113 CHEMBL1909172 (2)
1 / 0
P21452 Substance-K receptor Neurokinin receptor CHEMBL113 CHEMBL1909114 (2)
0 / 0
P51679 C-C chemokine receptor type 4 CC chemokine receptor CHEMBL113 CHEMBL1909125 (2)
0 / 0
P51681 C-C chemokine receptor type 5 CC chemokine receptor CHEMBL113 CHEMBL1909126 (2)
3 / 0
P50406 5-hydroxytryptamine receptor 6 Serotonin receptor CHEMBL113 CHEMBL1909108 (2)
0 / 0
P41597 C-C chemokine receptor type 2 CC chemokine receptor CHEMBL113 CHEMBL1909124 (2)
1 / 0
P28482 Mitogen-activated protein kinase 1 Erk CHEMBL113 CHEMBL1909200 (2)
0 / 0
P08575 Receptor-type tyrosine-protein phosphatase C Enzyme CHEMBL113 CHEMBL1909207 (2)
2 / 1
P05177 Cytochrome P450 1A2 Cytochrome P450 1A2 CHEMBL113 CHEMBL1743265 (1) CHEMBL1909132 (2)
CHEMBL2071962 (1)
0 / 0
O76074 cGMP-specific 3',5'-cyclic phosphodiesterase PDE_5A CHEMBL113 CHEMBL1909186 (2)
0 / 0
P03372 Estrogen receptor NR3A1 CHEMBL113 CHEMBL1909145 (2)
1 / 1
P08588 Beta-1 adrenergic receptor Adrenergic receptor CHEMBL113 CHEMBL1909091 (2)
1 / 0
P22303 Acetylcholinesterase Hydrolase CHEMBL113 CHEMBL1909212 (2)
1 / 0
P28223 5-hydroxytryptamine receptor 2A Serotonin receptor CHEMBL113 CHEMBL1909211 (2)
0 / 0
P28335 5-hydroxytryptamine receptor 2C Serotonin receptor CHEMBL113 CHEMBL1909105 (2)
0 / 0
P35372 Mu-type opioid receptor Opioid receptor CHEMBL113 CHEMBL1909182 (2)
0 / 0
P08173 Muscarinic acetylcholine receptor M4 Acetylcholine receptor CHEMBL113 CHEMBL1909173 (2)
0 / 0
P25103 Substance-P receptor Neurokinin receptor CHEMBL113 CHEMBL1909113 (2)
0 / 0
P25105 Platelet-activating factor receptor PAF receptor CHEMBL113 CHEMBL1909187 (2)
0 / 0
P33032 Melanocortin receptor 5 Melanocortin receptor CHEMBL113 CHEMBL1909168 (2)
0 / 0
P33261 Cytochrome P450 2C19 Cytochrome P450 2C19 CHEMBL113 CHEMBL1909134 (2) CHEMBL2071964 (1)
1 / 1
P08684 Cytochrome P450 3A4 Cytochrome P450 3A4 CHEMBL113 CHEMBL1909138 (2) CHEMBL2071966 (1)
CHEMBL2071967 (1)
0 / 1
P05181 Cytochrome P450 2E1 Cytochrome P450 2E1 CHEMBL113 CHEMBL1909137 (2)
0 / 0
P10275 Androgen receptor NR3C4 CHEMBL113 CHEMBL1794560 (1)
3 / 4
P23975 Sodium-dependent noradrenaline transporter Norepinephrine CHEMBL113 CHEMBL1909094 (2)
1 / 1
P25100 Alpha-1D adrenergic receptor Adrenergic receptor CHEMBL113 CHEMBL1909087 (2)
0 / 0
P30542 Adenosine receptor A1 Adenosine receptor CHEMBL113 CHEMBL633044 (1) CHEMBL643968 (1)
CHEMBL848253 (1) CHEMBL830050 (1)
CHEMBL831245 (1) CHEMBL947105 (1)
CHEMBL972850 (1) CHEMBL967544 (1)
CHEMBL1061437 (1) CHEMBL1909213 (2)
CHEMBL2156697 (1)
0 / 0
P18089 Alpha-2B adrenergic receptor Adrenergic receptor CHEMBL113 CHEMBL1909089 (2)
0 / 0
P24557 Thromboxane-A synthase Cytochrome P450 5A1 CHEMBL113 CHEMBL1909116 (2)
1 / 1
P06239 Tyrosine-protein kinase Lck Src CHEMBL113 CHEMBL1909206 (2)
0 / 1
P25025 C-X-C chemokine receptor type 2 CXC chemokine receptor CHEMBL113 CHEMBL1909128 (2)
0 / 0
P04156 Major prion protein Surface antigen CHEMBL113 CHEMBL2155230 (1)
6 / 2
Q9UBT6 DNA polymerase kappa Enzyme CHEMBL113 CHEMBL1794536 (1)
0 / 0
Q96KQ7 Histone-lysine N-methyltransferase EHMT2 Enzyme CHEMBL113 CHEMBL1738442 (3)
0 / 0
Q9NY46 Sodium channel protein type 3 subunit alpha SCN alpha, NaV1.x CHEMBL113 CHEMBL806152 (1) CHEMBL806153 (1)
0 / 0
Q99250 Sodium channel protein type 2 subunit alpha SCN alpha, NaV1.x CHEMBL113 CHEMBL806152 (1) CHEMBL806153 (1)
2 / 2
P35498 Sodium channel protein type 1 subunit alpha SCN alpha, NaV1.x CHEMBL113 CHEMBL806152 (1) CHEMBL806153 (1)
3 / 2

CTD interaction (197)

compound gene gene name gene description interaction interaction type form reference
pmid
D002110 39 ACAT2
acetyl-CoA acetyltransferase 2 (EC:2.3.1.9) Caffeine results in decreased expression of ACAT2 mRNA decreases expression
mRNA 11793227
D002110 22985 ACIN1
ACINUS
ACN
fSAP152
apoptotic chromatin condensation inducer 1 Caffeine results in increased expression of ACIN1 mRNA increases expression
mRNA 11793227
D002110 2181 ACSL3
ACS3
FACL3
PRO2194
acyl-CoA synthetase long-chain family member 3 (EC:6.2.1.3) Caffeine results in increased expression of ACSL3 mRNA increases expression
mRNA 11793227
D002110 135 ADORA2A
A2aR
ADORA2
RDC8
adenosine A2a receptor ADORA2A polymorphism affects the susceptibility to Caffeine affects response to substance
polymorphism 18305461
D002110 135 ADORA2A
A2aR
ADORA2
RDC8
adenosine A2a receptor ADORA2A polymorphism results in increased susceptibility to Caffeine increases response to substance
polymorphism 12825092
16221767
D002110 135 ADORA2A
A2aR
ADORA2
RDC8
adenosine A2a receptor ADORA2A SNP results in increased susceptibility to Caffeine increases response to substance
SNP 20520601
D002110 136 ADORA2B
ADORA2
adenosine A2b receptor ADORA2B mutant form inhibits the reaction [Caffeine results in decreased expression of and results in decreased activity of HSD11B2 protein] decreases activity
/ decreases expression
/ decreases reaction
mutant form 22701600
D002110 136 ADORA2B
ADORA2
adenosine A2b receptor ADORA2B mutant form inhibits the reaction [Caffeine results in decreased expression of HSD11B2 mRNA] decreases expression
/ decreases reaction
mutant form 22701600
D002110 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Caffeine results in increased phosphorylation of AKT1 protein] decreases reaction
/ increases phosphorylation
protein 18201823
D002110 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) AKT1 results in decreased susceptibility to Caffeine decreases response to substance
21561856
D002110 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Caffeine inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein] decreases reaction
/ increases phosphorylation
protein 21081844
D002110 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Caffeine results in decreased expression of AKT1 protein modified form decreases expression
protein 21081844
D002110 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Caffeine results in decreased phosphorylation of AKT1 protein decreases phosphorylation
protein 21081844
21561856
D002110 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) Caffeine results in increased phosphorylation of AKT1 protein increases phosphorylation
protein 18201823
D002110 207 AKT1
AKT
CWS6
PKB
PKB-ALPHA
PRKBA
RAC
RAC-ALPHA
v-akt murine thymoma viral oncogene homolog 1 (EC:2.7.11.1) wortmannin inhibits the reaction [Caffeine results in increased phosphorylation of AKT1 protein] decreases reaction
/ increases phosphorylation
protein 18201823
D002110 5832 ALDH18A1
ARCL3A
GSAS
P5CS
PYCS
aldehyde dehydrogenase 18 family, member A1 (EC:1.2.1.41 2.7.2.11) Caffeine results in decreased expression of ALDH18A1 mRNA decreases expression
mRNA 11793227
D002110 283 ANG
ALS9
HEL168
RNASE4
RNASE5
angiogenin, ribonuclease, RNase A family, 5 (EC:3.1.27.-) Caffeine results in decreased expression of ANG mRNA decreases expression
mRNA 11793227
D002110 335 APOA1
apolipoprotein A-I [Ephedrine co-treated with Caffeine] results in increased expression of APOA1 protein affects cotreatment
/ increases expression
protein 16324916
D002110 336 APOA2
Apo-AII
ApoA-II
apoAII
apolipoprotein A-II [Ephedrine co-treated with Caffeine] results in decreased expression of APOA2 protein affects cotreatment
/ decreases expression
protein 16324916
D002110 338 APOB
FLDB
LDLCQ4
apolipoprotein B [Ephedrine co-treated with Caffeine] results in decreased expression of APOB protein affects cotreatment
/ decreases expression
protein 16324916
D002110 341 APOC1
apolipoprotein C-I [Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in increased expression of APOC1 protein affects cotreatment
/ increases expression
protein 16324916
D002110 344 APOC2
APO-CII
APOC-II
apolipoprotein C-II [Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC2 protein affects cotreatment
/ decreases expression
protein 16324916
D002110 345 APOC3
APOCIII
HALP2
apolipoprotein C-III [Ephedrine co-treated with Caffeine co-treated with pioglitazone] results in decreased expression of APOC3 protein affects cotreatment
/ decreases expression
protein 16324916
D002110 23204 ARL6IP1
AIP1
ARL6IP
ARMER
ADP-ribosylation factor-like 6 interacting protein 1 Caffeine results in increased expression of ARL6IP1 mRNA increases expression
mRNA 11793227
D002110 440 ASNS
TS11
asparagine synthetase (glutamine-hydrolyzing) (EC:6.3.5.4) Caffeine results in decreased expression of ASNS mRNA decreases expression
mRNA 18444173
D002110 472 ATM
AT1
ATA
ATC
ATD
ATDC
ATE
TEL1
TELO1
ataxia telangiectasia mutated (EC:2.7.11.1) Caffeine inhibits the reaction [(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine results in increased phosphorylation of ATM protein] decreases reaction
/ increases phosphorylation
protein 23274516
D002110 472 ATM
AT1
ATA
ATC
ATD
ATDC
ATE
TEL1
TELO1
ataxia telangiectasia mutated (EC:2.7.11.1) Caffeine inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in decreased activity of ATM protein] decreases activity
/ decreases reaction
/ increases phosphorylation
protein 18347191
D002110 472 ATM
AT1
ATA
ATC
ATD
ATDC
ATE
TEL1
TELO1
ataxia telangiectasia mutated (EC:2.7.11.1) Caffeine inhibits the reaction [Genistein results in increased phosphorylation of ATM protein] decreases reaction
/ increases phosphorylation
protein 19038232
D002110 472 ATM
AT1
ATA
ATC
ATD
ATDC
ATE
TEL1
TELO1
ataxia telangiectasia mutated (EC:2.7.11.1) Caffeine inhibits the reaction [kaempferol results in increased phosphorylation of ATM protein] decreases reaction
/ increases phosphorylation
protein 19028473
D002110 472 ATM
AT1
ATA
ATC
ATD
ATDC
ATE
TEL1
TELO1
ataxia telangiectasia mutated (EC:2.7.11.1) Caffeine inhibits the reaction [resveratrol results in increased activity of [ATM protein co-treated with ATR protein]] affects cotreatment
/ decreases reaction
/ increases activity
protein 15975956
D002110 472 ATM
AT1
ATA
ATC
ATD
ATDC
ATE
TEL1
TELO1
ataxia telangiectasia mutated (EC:2.7.11.1) Caffeine inhibits the reaction [[resveratrol results in increased activity of [ATM protein co-treated with ATR protein]] results in increased activity of [CHEK1 protein co-treated with CHEK2 protein]] affects cotreatment
/ decreases reaction
/ increases activity
protein 15975956
D002110 472 ATM
AT1
ATA
ATC
ATD
ATDC
ATE
TEL1
TELO1
ataxia telangiectasia mutated (EC:2.7.11.1) Caffeine results in decreased activity of ATM protein decreases activity
protein 10531013
11507241
D002110 472 ATM
AT1
ATA
ATC
ATD
ATDC
ATE
TEL1
TELO1
ataxia telangiectasia mutated (EC:2.7.11.1) [[Caffeine results in decreased activity of ATR protein] co-treated with [Caffeine results in decreased activity of ATM protein]] results in decreased susceptibility to Acrylamide affects cotreatment
/ decreases activity
/ decreases response to substance
protein 20734998
D002110 9551 ATP5J2
ATP5JL
ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F2 (EC:3.6.1.14) Caffeine results in decreased expression of ATP5J2 mRNA decreases expression
mRNA 11793227
D002110 545 ATR
FCTCS
FRP1
MEC1
SCKL
SCKL1
ataxia telangiectasia and Rad3 related (EC:2.7.11.1) Caffeine affects the activity of ATR protein affects activity
protein 11507241
D002110 545 ATR
FCTCS
FRP1
MEC1
SCKL
SCKL1
ataxia telangiectasia and Rad3 related (EC:2.7.11.1) Caffeine inhibits the reaction [Hydroxyurea promotes the reaction [ATR protein results in increased phosphorylation of and results in increased activity of CHEK1 protein]] decreases reaction
/ increases activity
/ increases phosphorylation
/ increases reaction
protein 18158334
D002110 545 ATR
FCTCS
FRP1
MEC1
SCKL
SCKL1
ataxia telangiectasia and Rad3 related (EC:2.7.11.1) Caffeine inhibits the reaction [resveratrol results in increased activity of [ATM protein co-treated with ATR protein]] affects cotreatment
/ decreases reaction
/ increases activity
protein 15975956
D002110 545 ATR
FCTCS
FRP1
MEC1
SCKL
SCKL1
ataxia telangiectasia and Rad3 related (EC:2.7.11.1) Caffeine inhibits the reaction [[resveratrol results in increased activity of [ATM protein co-treated with ATR protein]] results in increased activity of [CHEK1 protein co-treated with CHEK2 protein]] affects cotreatment
/ decreases reaction
/ increases activity
protein 15975956
D002110 545 ATR
FCTCS
FRP1
MEC1
SCKL
SCKL1
ataxia telangiectasia and Rad3 related (EC:2.7.11.1) [[Caffeine results in decreased activity of ATR protein] co-treated with [Caffeine results in decreased activity of ATM protein]] results in decreased susceptibility to Acrylamide affects cotreatment
/ decreases activity
/ decreases response to substance
protein 20734998
D002110 581 BAX
BCL2L4
BCL2-associated X protein Caffeine results in increased expression of BAX protein increases expression
protein 12811820
D002110 27113 BBC3
JFY-1
JFY1
PUMA
BCL2 binding component 3 Caffeine inhibits the reaction [kaempferol results in increased expression of BBC3 protein] decreases reaction
/ increases expression
protein 19028473
D002110 637 BID
FP497
BH3 interacting domain death agonist Caffeine inhibits the reaction [silybin results in increased cleavage of BID protein] decreases reaction
/ increases cleavage
protein 16777994
D002110 699 BUB1
BUB1A
BUB1L
hBUB1
BUB1 mitotic checkpoint serine/threonine kinase (EC:2.7.11.1) [Nocodazole co-treated with Caffeine] results in increased expression of BUB1 protein modified form affects cotreatment
/ increases expression
protein 21670593
D002110 813 CALU
calumenin Caffeine results in decreased expression of CALU mRNA decreases expression
mRNA 11793227
D002110 823 CAPN1
CANP
CANP1
CANPL1
muCANP
muCL
calpain 1, (mu/I) large subunit (EC:3.4.22.52) [Caffeine co-treated with Alprazolam] promotes the reaction [Calcium results in increased activity of CAPN1 protein] affects cotreatment
/ increases activity
/ increases reaction
protein 19490937
D002110 835 CASP2
CASP-2
ICH1
NEDD-2
NEDD2
PPP1R57
caspase 2, apoptosis-related cysteine peptidase (EC:3.4.22.55) Caffeine inhibits the reaction [silybin results in increased cleavage of and results in increased activity of CASP2 protein] decreases reaction
/ increases activity
/ increases cleavage
protein 16777994
D002110 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Caffeine affects the cleavage of CASP3 protein affects cleavage
protein 19242509
D002110 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) [Caffeine co-treated with Alprazolam] results in increased cleavage of CASP3 protein affects cotreatment
/ increases cleavage
protein 19490937
D002110 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Caffeine inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein] decreases reaction
/ increases activity
protein 18201823
D002110 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Caffeine inhibits the reaction [silybin results in increased cleavage of and results in increased activity of CASP3 protein] decreases reaction
/ increases activity
/ increases cleavage
protein 16777994
D002110 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Caffeine results in increased activity of CASP3 protein increases activity
protein 12378022
21229324
D002110 836 CASP3
CPP32
CPP32B
SCA-1
caspase 3, apoptosis-related cysteine peptidase (EC:3.4.22.56) Caffeine results in increased cleavage of and results in increased expression of CASP3 protein increases cleavage
/ increases expression
protein 16522534
D002110 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) Caffeine inhibits the reaction [silybin results in increased cleavage of and results in increased activity of CASP9 protein] decreases reaction
/ increases activity
/ increases cleavage
protein 16777994
D002110 842 CASP9
APAF-3
APAF3
ICE-LAP6
MCH6
PPP1R56
caspase 9, apoptosis-related cysteine peptidase (EC:3.4.22.62) Caffeine results in increased cleavage of and results in increased expression of CASP9 protein increases cleavage
/ increases expression
protein 16522534
D002110 891 CCNB1
CCNB
cyclin B1 Caffeine inhibits the reaction [Genistein results in increased expression of CCNB1 protein] decreases reaction
/ increases expression
protein 19038232
D002110 995 CDC25C
CDC25
PPP1R60
cell division cycle 25C (EC:3.1.3.48) Caffeine inhibits the reaction [CDC25C protein binds to YWHAQ protein] affects binding
/ decreases reaction
protein 11835680
D002110 995 CDC25C
CDC25
PPP1R60
cell division cycle 25C (EC:3.1.3.48) Caffeine inhibits the reaction [resveratrol results in increased phosphorylation of CDC25C protein] decreases reaction
/ increases phosphorylation
protein 15975956
D002110 995 CDC25C
CDC25
PPP1R60
cell division cycle 25C (EC:3.1.3.48) Caffeine results in decreased expression of CDC25C protein decreases expression
protein 11835680
D002110 983 CDK1
CDC2
CDC28A
P34CDC2
cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) Caffeine inhibits the reaction [Genistein results in increased phosphorylation of CDK1 protein] decreases reaction
/ increases phosphorylation
protein 19038232
D002110 983 CDK1
CDC2
CDC28A
P34CDC2
cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) Caffeine inhibits the reaction [resveratrol results in increased phosphorylation of CDK1 protein] decreases reaction
/ increases phosphorylation
protein 15975956
D002110 983 CDK1
CDC2
CDC28A
P34CDC2
cyclin-dependent kinase 1 (EC:2.7.11.23 2.7.11.22) Caffeine results in decreased phosphorylation of and results in increased activity of CDK1 protein decreases phosphorylation
/ increases activity
protein 11835680
D002110 1017 CDK2
p33(CDK2)
cyclin-dependent kinase 2 (EC:2.7.11.22) Caffeine results in decreased activity of CDK2 protein decreases activity
protein 11835680
D002110 1019 CDK4
CMM3
PSK-J3
cyclin-dependent kinase 4 (EC:2.7.11.22) Caffeine results in decreased expression of CDK4 mRNA decreases expression
mRNA 11793227
D002110 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Caffeine inhibits the reaction [(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine results in increased expression of CDKN1A protein] decreases reaction
/ increases expression
protein 23274516
D002110 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Caffeine inhibits the reaction [Cytarabine results in increased expression of CDKN1A protein] decreases reaction
/ increases expression
protein 17977830
D002110 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Caffeine inhibits the reaction [decitabine results in increased expression of CDKN1A protein] decreases reaction
/ increases expression
protein 18223691
D002110 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Caffeine inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein] decreases reaction
/ increases expression
protein 18347191
D002110 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Caffeine inhibits the reaction [entinostat results in increased expression of CDKN1A protein] decreases reaction
/ increases expression
protein 18223691
D002110 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) Caffeine inhibits the reaction [oxaliplatin results in increased expression of CDKN1A protein] decreases reaction
/ increases expression
protein 19735649
D002110 1111 CHEK1
CHK1
checkpoint kinase 1 (EC:2.7.11.1) Caffeine inhibits the reaction [Carmustine results in increased phosphorylation of and results in increased activity of CHEK1 protein] decreases reaction
/ increases activity
/ increases phosphorylation
protein 19261750
D002110 1111 CHEK1
CHK1
checkpoint kinase 1 (EC:2.7.11.1) Caffeine inhibits the reaction [Hydroxyurea promotes the reaction [ATR protein results in increased phosphorylation of and results in increased activity of CHEK1 protein]] decreases reaction
/ increases activity
/ increases phosphorylation
/ increases reaction
protein 18158334
D002110 1111 CHEK1
CHK1
checkpoint kinase 1 (EC:2.7.11.1) Caffeine inhibits the reaction [[resveratrol results in increased activity of [ATM protein co-treated with ATR protein]] results in increased activity of [CHEK1 protein co-treated with CHEK2 protein]] affects cotreatment
/ decreases reaction
/ increases activity
protein 15975956
D002110 1111 CHEK1
CHK1
checkpoint kinase 1 (EC:2.7.11.1) Caffeine inhibits the reaction [resveratrol results in increased activity of [CHEK1 protein co-treated with CHEK2 protein]] affects cotreatment
/ decreases reaction
/ increases activity
protein 15975956
D002110 1111 CHEK1
CHK1
checkpoint kinase 1 (EC:2.7.11.1) Caffeine results in decreased phosphorylation of CHEK1 protein decreases phosphorylation
protein 21561856
D002110 11200 CHEK2
CDS1
CHK2
HuCds1
LFS2
PP1425
RAD53
hCds1
checkpoint kinase 2 (EC:2.7.11.1) Caffeine inhibits the reaction [(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine results in increased phosphorylation of CHEK2 protein] decreases reaction
/ increases phosphorylation
protein 23274516
D002110 11200 CHEK2
CDS1
CHK2
HuCds1
LFS2
PP1425
RAD53
hCds1
checkpoint kinase 2 (EC:2.7.11.1) Caffeine inhibits the reaction [Genistein results in increased phosphorylation of CHEK2 protein] decreases reaction
/ increases phosphorylation
protein 19038232
D002110 11200 CHEK2
CDS1
CHK2
HuCds1
LFS2
PP1425
RAD53
hCds1
checkpoint kinase 2 (EC:2.7.11.1) Caffeine inhibits the reaction [[resveratrol results in increased activity of [ATM protein co-treated with ATR protein]] results in increased activity of [CHEK1 protein co-treated with CHEK2 protein]] affects cotreatment
/ decreases reaction
/ increases activity
protein 15975956
D002110 11200 CHEK2
CDS1
CHK2
HuCds1
LFS2
PP1425
RAD53
hCds1
checkpoint kinase 2 (EC:2.7.11.1) Caffeine inhibits the reaction [resveratrol results in increased activity of [CHEK1 protein co-treated with CHEK2 protein]] affects cotreatment
/ decreases reaction
/ increases activity
protein 15975956
D002110 11200 CHEK2
CDS1
CHK2
HuCds1
LFS2
PP1425
RAD53
hCds1
checkpoint kinase 2 (EC:2.7.11.1) Caffeine inhibits the reaction [silybin results in increased phosphorylation of CHEK2 protein] decreases reaction
/ increases phosphorylation
protein 16777994
D002110 11200 CHEK2
CDS1
CHK2
HuCds1
LFS2
PP1425
RAD53
hCds1
checkpoint kinase 2 (EC:2.7.11.1) Caffeine promotes the reaction [Aphidicolin promotes the reaction [PRKDC protein results in increased phosphorylation of and results in increased activity of CHEK2 protein]] increases activity
/ increases phosphorylation
/ increases reaction
protein 18158334
D002110 11200 CHEK2
CDS1
CHK2
HuCds1
LFS2
PP1425
RAD53
hCds1
checkpoint kinase 2 (EC:2.7.11.1) Caffeine results in decreased activity of CHEK2 protein decreases activity
protein 10531013
D002110 1508 CTSB
APPS
CPSB
cathepsin B (EC:3.4.22.1) [Caffeine co-treated with Alprazolam] results in increased secretion of CTSB protein affects cotreatment
/ increases secretion
protein 19490937
D002110 1537 CYC1
MC3DN6
UQCR4
cytochrome c-1 Caffeine results in decreased expression of CYC1 mRNA decreases expression
mRNA 11793227
D002110 54205 CYCS
CYC
HCS
THC4
cytochrome c, somatic Caffeine inhibits the reaction [kaempferol affects the localization of CYCS protein] affects localization
/ decreases reaction
protein 19028473
D002110 1544 CYP1A2
CP12
P3-450
P450(PA)
cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) Caffeine results in decreased activity of CYP1A2 protein decreases activity
protein 11465391
D002110 1544 CYP1A2
CP12
P3-450
P450(PA)
cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) Ciprofloxacin inhibits the reaction [CYP1A2 protein results in decreased methylation of Caffeine] decreases methylation
/ decreases reaction
protein 11145498
D002110 1544 CYP1A2
CP12
P3-450
P450(PA)
cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) CYP1A2 protein affects the metabolism of Caffeine affects metabolic processing
protein 1302044
14586384
14586387
15022032
15199075
15286053
15327588
15980104
D002110 1544 CYP1A2
CP12
P3-450
P450(PA)
cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) CYP1A2 protein affects the metabolism of Caffeine metabolite affects metabolic processing
protein 1302044
D002110 1544 CYP1A2
CP12
P3-450
P450(PA)
cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) CYP1A2 protein binds to and affects the metabolism of Caffeine affects binding
/ affects metabolic processing
protein 15659567
15856409
D002110 1544 CYP1A2
CP12
P3-450
P450(PA)
cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) CYP1A2 protein binds to Caffeine affects binding
protein 9334905
D002110 1544 CYP1A2
CP12
P3-450
P450(PA)
cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) CYP1A2 protein results in decreased methylation of Caffeine decreases methylation
protein 11145498
12433797
D002110 1544 CYP1A2
CP12
P3-450
P450(PA)
cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) CYP1A2 protein results in increased metabolism of Caffeine increases metabolic processing
protein 11907490
20716633
D002110 1544 CYP1A2
CP12
P3-450
P450(PA)
cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) GH1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of Caffeine] increases metabolic processing
/ increases reaction
protein 11907490
D002110 1544 CYP1A2
CP12
P3-450
P450(PA)
cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) resveratrol promotes the reaction [CYP1A2 protein results in increased metabolism of Caffeine] increases metabolic processing
/ increases reaction
protein 20716633
D002110 1544 CYP1A2
CP12
P3-450
P450(PA)
cytochrome P450, family 1, subfamily A, polypeptide 2 (EC:1.14.14.1) rofecoxib inhibits the reaction [CYP1A2 protein results in increased metabolism of Caffeine] decreases reaction
/ increases metabolic processing
protein 16934051
D002110 1548 CYP2A6
CPA6
CYP2A
CYP2A3
CYPIIA6
P450C2A
P450PB
cytochrome P450, family 2, subfamily A, polypeptide 6 (EC:1.14.14.1) CYP2A6 protein affects the metabolism of and results in increased activity of Caffeine metabolite affects metabolic processing
/ increases activity
protein 12505289
D002110 1548 CYP2A6
CPA6
CYP2A
CYP2A3
CYPIIA6
P450C2A
P450PB
cytochrome P450, family 2, subfamily A, polypeptide 6 (EC:1.14.14.1) CYP2A6 protein results in increased metabolism of Caffeine increases metabolic processing
protein 17916905
D002110 1565 CYP2D6
CPD6
CYP2D
CYP2D7AP
CYP2D7BP
CYP2D7P2
CYP2D8P2
CYP2DL1
CYPIID6
P450-DB1
P450C2D
P450DB1
cytochrome P450, family 2, subfamily D, polypeptide 6 (EC:1.14.14.1) CYP2D6 protein affects the metabolism of Caffeine affects metabolic processing
protein 15199075
D002110 1571 CYP2E1
CPE1
CYP2E
P450-J
P450C2E
cytochrome P450, family 2, subfamily E, polypeptide 1 (EC:1.14.13.n7) CYP2E1 protein affects the metabolism of Caffeine affects metabolic processing
protein 1302044
14586387
D002110 1580 CYP4B1
CYPIVB1
P-450HP
cytochrome P450, family 4, subfamily B, polypeptide 1 (EC:1.14.14.1) Caffeine results in increased expression of CYP4B1 mRNA increases expression
mRNA 18444173
D002110 1603 DAD1
OST2
defender against cell death 1 (EC:2.4.99.18) Caffeine results in decreased expression of DAD1 mRNA decreases expression
mRNA 11793227
D002110 1638 DCT
TRP-2
TYRP2
dopachrome tautomerase (EC:5.3.3.12) Caffeine results in increased expression of DCT mRNA increases expression
mRNA 18444173
D002110 1813 DRD2
D2DR
D2R
dopamine receptor D2 DRD2 polymorphism affects the susceptibility to Caffeine affects response to substance
polymorphism 18305461
D002110 10209 EIF1
A121
EIF-1
EIF1A
ISO1
SUI1
eukaryotic translation initiation factor 1 Caffeine results in increased expression of EIF1 mRNA increases expression
mRNA 11793227
D002110 1978 EIF4EBP1
4E-BP1
4EBP1
BP-1
PHAS-I
eukaryotic translation initiation factor 4E binding protein 1 Caffeine results in decreased expression of EIF4EBP1 protein modified form decreases expression
protein 21081844
D002110 1978 EIF4EBP1
4E-BP1
4EBP1
BP-1
PHAS-I
eukaryotic translation initiation factor 4E binding protein 1 Caffeine results in increased expression of EIF4EBP1 protein increases expression
protein 21081844
D002110 2688 GH1
GH
GH-N
GHN
IGHD1B
hGH-N
growth hormone 1 GH1 protein promotes the reaction [CYP1A2 protein results in increased metabolism of Caffeine] increases metabolic processing
/ increases reaction
protein 11907490
D002110 2745 GLRX
GRX
GRX1
glutaredoxin (thioltransferase) (EC:1.8.4.1) Caffeine results in decreased expression of GLRX mRNA decreases expression
mRNA 11793227
D002110 55830 GLT8D1
MSTP139
glycosyltransferase 8 domain containing 1 Caffeine results in decreased expression of GLT8D1 mRNA decreases expression
mRNA 11793227
D002110 2746 GLUD1
GDH
GDH1
GLUD
glutamate dehydrogenase 1 (EC:1.4.1.3) Caffeine results in decreased expression of GLUD1 mRNA decreases expression
mRNA 11793227
D002110 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) Caffeine results in increased phosphorylation of GSK3B protein increases phosphorylation
protein 21229324
D002110 2932 GSK3B
glycogen synthase kinase 3 beta (EC:2.7.11.1 2.7.11.26) N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Caffeine results in increased phosphorylation of GSK3B protein] decreases reaction
/ increases phosphorylation
protein 21229324
D002110 9446 GSTO1
GSTO_1-1
GSTTLp28
P28
SPG-R
glutathione S-transferase omega 1 (EC:2.5.1.18 1.8.5.1 1.20.4.2) Caffeine results in decreased expression of GSTO1 mRNA decreases expression
mRNA 11793227
D002110 3014 H2AFX
H2A.X
H2A/X
H2AX
H2A histone family, member X Caffeine inhibits the reaction [resveratrol results in increased phosphorylation of H2AFX protein] decreases reaction
/ increases phosphorylation
protein 15975956
D002110 3014 H2AFX
H2A.X
H2A/X
H2AX
H2A histone family, member X Caffeine inhibits the reaction [silybin results in increased phosphorylation of H2AFX protein] decreases reaction
/ increases phosphorylation
protein 16777994
D002110 3014 H2AFX
H2A.X
H2A/X
H2AX
H2A histone family, member X Caffeine promotes the reaction [Benzo(a)pyrene results in increased phosphorylation of H2AFX protein] increases phosphorylation
/ increases reaction
protein 20888899
D002110 3291 HSD11B2
AME
AME1
HSD11K
HSD2
SDR9C3
hydroxysteroid (11-beta) dehydrogenase 2 (EC:1.1.1.146) ADORA2B mutant form inhibits the reaction [Caffeine results in decreased expression of and results in decreased activity of HSD11B2 protein] decreases activity
/ decreases expression
/ decreases reaction
protein 22701600
D002110 3291 HSD11B2
AME
AME1
HSD11K
HSD2
SDR9C3
hydroxysteroid (11-beta) dehydrogenase 2 (EC:1.1.1.146) ADORA2B mutant form inhibits the reaction [Caffeine results in decreased expression of HSD11B2 mRNA] decreases expression
/ decreases reaction
mRNA 22701600
D002110 3291 HSD11B2
AME
AME1
HSD11K
HSD2
SDR9C3
hydroxysteroid (11-beta) dehydrogenase 2 (EC:1.1.1.146) Caffeine results in decreased expression of and results in decreased activity of HSD11B2 protein decreases activity
/ decreases expression
protein 22701600
D002110 3291 HSD11B2
AME
AME1
HSD11K
HSD2
SDR9C3
hydroxysteroid (11-beta) dehydrogenase 2 (EC:1.1.1.146) Caffeine results in decreased expression of HSD11B2 mRNA decreases expression
mRNA 22701600
D002110 3291 HSD11B2
AME
AME1
HSD11K
HSD2
SDR9C3
hydroxysteroid (11-beta) dehydrogenase 2 (EC:1.1.1.146) Colforsin inhibits the reaction [Caffeine results in decreased expression of and results in decreased activity of HSD11B2 protein] decreases activity
/ decreases expression
/ decreases reaction
protein 22701600
D002110 3291 HSD11B2
AME
AME1
HSD11K
HSD2
SDR9C3
hydroxysteroid (11-beta) dehydrogenase 2 (EC:1.1.1.146) Colforsin inhibits the reaction [Caffeine results in decreased expression of HSD11B2 mRNA] decreases expression
/ decreases reaction
mRNA 22701600
D002110 3484 IGFBP1
AFBP
IBP1
IGF-BP25
PP12
hIGFBP-1
insulin-like growth factor binding protein 1 Caffeine results in increased expression of IGFBP1 mRNA increases expression
mRNA 11793227
D002110 3630 INS
IDDM2
ILPR
IRDN
MODY10
insulin Caffeine inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein] decreases reaction
/ increases phosphorylation
protein 21081844
D002110 3708 ITPR1
INSP3R1
IP3R
IP3R1
SCA15
SCA16
SCA29
inositol 1,4,5-trisphosphate receptor, type 1 Caffeine results in decreased expression of ITPR1 mRNA decreases expression
mRNA 18444173
D002110 3939 LDHA
GSD11
LDH1
LDHM
lactate dehydrogenase A (EC:1.1.1.27) Caffeine results in decreased expression of LDHA mRNA decreases expression
mRNA 11793227
D002110 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) Caffeine results in increased expression of MAPK1 protein modified form increases expression
protein 21081844
D002110 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) Caffeine results in increased expression of MAPK3 protein modified form increases expression
protein 21081844
D002110 4257 MGST1
GST12
MGST
MGST-I
microsomal glutathione S-transferase 1 (EC:2.5.1.18) Caffeine results in decreased expression of MGST1 mRNA decreases expression
mRNA 11793227
D002110 4277 MICB
PERB11.2
MHC class I polypeptide-related sequence B Caffeine inhibits the reaction [[decitabine results in decreased methylation of MICB promoter] which results in increased expression of MICB protein] decreases methylation
/ decreases reaction
/ increases expression
promoter / protein 18395517
D002110 4495 MT1G
MT1
MT1K
metallothionein 1G Caffeine results in increased expression of MT1G mRNA increases expression
mRNA 11793227
D002110 2475 MTOR
FRAP
FRAP1
FRAP2
RAFT1
RAPT1
mechanistic target of rapamycin (serine/threonine kinase) (EC:2.7.11.1) Caffeine results in decreased activity of MTOR protein decreases activity
protein 21081844
D002110 10 NAT2
AAC2
NAT-2
PNAT
N-acetyltransferase 2 (arylamine N-acetyltransferase) (EC:2.3.1.5) NAT2 protein affects the metabolism of Caffeine affects metabolic processing
protein 14586384
14586387
14747882
15199075
15327588
15980104
D002110 10 NAT2
AAC2
NAT-2
PNAT
N-acetyltransferase 2 (arylamine N-acetyltransferase) (EC:2.3.1.5) NAT2 protein results in increased acetylation of Caffeine increases acetylation
protein 15558239
D002110 4942 OAT
GACR
HOGA
OATASE
OKT
ornithine aminotransferase (EC:2.6.1.13) Caffeine results in increased expression of OAT mRNA increases expression
mRNA 11793227
D002110 5062 PAK2
PAK65
PAKgamma
p21 protein (Cdc42/Rac)-activated kinase 2 (EC:2.7.11.1) Caffeine results in increased activity of PAK2 protein increases activity
protein 19325779
D002110 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) Caffeine affects the cleavage of PARP1 protein affects cleavage
protein 19242509
D002110 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) [Caffeine co-treated with Alprazolam] results in increased activity of PARP1 protein affects cotreatment
/ increases activity
protein 19490937
D002110 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) Caffeine promotes the reaction [Capsaicin results in increased cleavage of and results in increased activity of PARP1 protein] increases activity
/ increases cleavage
/ increases reaction
protein 22226932
D002110 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) Caffeine results in increased cleavage of and results in increased expression of PARP1 protein increases cleavage
/ increases expression
protein 16522534
D002110 142 PARP1
ADPRT
ADPRT_1
ADPRT1
ARTD1
PARP
PARP-1
PPOL
pADPRT-1
poly (ADP-ribose) polymerase 1 (EC:2.4.2.30) Caffeine results in increased cleavage of PARP1 protein increases cleavage
protein 21229324
D002110 5354 PLP1
GPM6C
HLD1
MMPL
PLP
PLP/DM20
PMD
SPG2
proteolipid protein 1 Caffeine results in increased expression of PLP1 mRNA increases expression
mRNA 18444173
D002110 5521 PPP2R2B
B55BETA
PP2AB55BETA
PP2ABBETA
PP2APR55B
PP2APR55BETA
PR2AB55BETA
PR2ABBETA
PR2APR55BETA
PR52B
PR55-BETA
PR55BETA
SCA12
protein phosphatase 2, regulatory subunit B, beta (EC:3.1.3.16) Caffeine results in decreased expression of PPP2R2B mRNA decreases expression
mRNA 18444173
D002110 27166 PRELID1
PRELI
PX19
SBBI12
PRELI domain containing 1 Caffeine results in decreased expression of PRELID1 mRNA decreases expression
mRNA 11793227
D002110 5591 PRKDC
DNA-PKcs
DNAPK
DNPK1
HYRC
HYRC1
XRCC7
p350
protein kinase, DNA-activated, catalytic polypeptide (EC:2.7.11.1) Caffeine promotes the reaction [Aphidicolin promotes the reaction [PRKDC protein results in increased phosphorylation of and results in increased activity of CHEK2 protein]] increases activity
/ increases phosphorylation
/ increases reaction
protein 18158334
D002110 5621 PRNP
ASCR
AltPrP
CD230
CJD
GSS
KURU
PRIP
PrP
PrP27-30
PrP33-35C
PrPc
p27-30
prion protein Caffeine results in decreased expression of PRNP mRNA decreases expression
mRNA 18444173
D002110 10197 PSME3
Ki
PA28-gamma
PA28G
PA28gamma
REG-GAMMA
proteasome (prosome, macropain) activator subunit 3 (PA28 gamma; Ki) Caffeine results in decreased expression of PSME3 mRNA decreases expression
mRNA 11793227
D002110 5743 PTGS2
COX-2
COX2
GRIPGHS
PGG/HS
PGHS-2
PHS-2
hCox-2
prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) (EC:1.14.99.1) Caffeine results in decreased expression of PTGS2 protein decreases expression
protein 21561856
D002110 5925 RB1
OSRC
RB
p105-Rb
pRb
pp110
retinoblastoma 1 Caffeine results in decreased phosphorylation of RB1 protein decreases phosphorylation
protein 21229324
D002110 5972 REN
HNFJ2
renin (EC:3.4.23.15) Caffeine results in increased activity of REN protein increases activity
protein 8244516
D002110 6194 RPS6
S6
ribosomal protein S6 Caffeine results in decreased expression of RPS6 protein modified form decreases expression
protein 21081844
D002110 6197 RPS6KA3
CLS
HU-3
ISPK-1
MAPKAPK1B
MRX19
RSK
RSK2
S6K-alpha3
p90-RSK2
pp90RSK2
ribosomal protein S6 kinase, 90kDa, polypeptide 3 (EC:2.7.11.1) Caffeine results in decreased expression of RPS6KA3 mRNA decreases expression
mRNA 11793227
D002110 6198 RPS6KB1
PS6K
S6K
S6K-beta-1
S6K1
STK14A
p70_S6KA
p70(S6K)-alpha
p70-S6K
p70-alpha
ribosomal protein S6 kinase, 70kDa, polypeptide 1 (EC:2.7.11.1) Caffeine results in decreased expression of RPS6KB1 protein modified form decreases expression
protein 21081844
D002110 23212 RRS1
RRS1 ribosome biogenesis regulator homolog (S. cerevisiae) Caffeine results in increased expression of RRS1 mRNA increases expression
mRNA 11793227
D002110 6261 RYR1
CCO
MHS
MHS1
RYDR
RYR
RYR-1
SKRR
ryanodine receptor 1 (skeletal) Caffeine results in increased activity of RYR1 protein increases activity
protein 21485675
D002110 6261 RYR1
CCO
MHS
MHS1
RYDR
RYR
RYR-1
SKRR
ryanodine receptor 1 (skeletal) [Caffeine results in increased activity of RYR1 protein] which affects the localization of Calcium affects localization
/ increases activity
protein 21485675
D002110 6261 RYR1
CCO
MHS
MHS1
RYDR
RYR
RYR-1
SKRR
ryanodine receptor 1 (skeletal) RYR1 gene mutant form results in increased susceptibility to Caffeine increases response to substance
gene 19191329
D002110 6261 RYR1
CCO
MHS
MHS1
RYDR
RYR
RYR-1
SKRR
ryanodine receptor 1 (skeletal) RYR1 protein mutant form results in increased susceptibility to Caffeine increases response to substance
protein 14641996
15210166
18719443
D002110 6261 RYR1
CCO
MHS
MHS1
RYDR
RYR
RYR-1
SKRR
ryanodine receptor 1 (skeletal) RYR1 protein polymorphism affects the reaction [Caffeine results in increased secretion of Calcium] affects reaction
/ increases secretion
protein 16372898
D002110 23256 SCFD1
C14orf163
RA410
SLY1
SLY1P
STXBP1L2
sec1 family domain containing 1 Caffeine results in decreased expression of SCFD1 mRNA decreases expression
mRNA 11793227
D002110 6396 SEC13
D3S1231E
SEC13L1
SEC13R
npp-20
SEC13 homolog (S. cerevisiae) Caffeine results in decreased expression of SEC13 mRNA decreases expression
mRNA 11793227
D002110 10484 SEC23A
CLSD
Sec23 homolog A (S. cerevisiae) Caffeine results in decreased expression of SEC23A mRNA decreases expression
mRNA 11793227
D002110 5265 SERPINA1
A1A
A1AT
AAT
PI
PI1
PRO2275
alpha1AT
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1 Caffeine results in increased expression of SERPINA1 mRNA increases expression
mRNA 18444173
D002110 866 SERPINA6
CBG
serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6 Caffeine results in decreased expression of SERPINA6 mRNA decreases expression
mRNA 11793227
D002110 6566 SLC16A1
HHF7
MCT
MCT1
solute carrier family 16 (monocarboxylate transporter), member 1 Caffeine affects the reaction [SLC16A1 protein results in increased uptake of Butyrates] affects reaction
/ increases uptake
protein 19023563
D002110 6566 SLC16A1
HHF7
MCT
MCT1
solute carrier family 16 (monocarboxylate transporter), member 1 Caffeine results in increased expression of SLC16A1 mRNA increases expression
mRNA 19023563
D002110 54498 SMOX
C20orf16
PAO
PAO-1
PAOH1
SMO
spermine oxidase (EC:1.5.3.16) Caffeine results in increased expression of SMOX mRNA increases expression
mRNA 11793227
D002110 6713 SQLE
squalene epoxidase (EC:1.14.13.132) Caffeine results in decreased expression of SQLE mRNA decreases expression
mRNA 11793227
D002110 8878 SQSTM1
A170
OSIL
PDB3
ZIP3
p60
p62
p62B
sequestosome 1 Caffeine results in decreased expression of SQSTM1 protein decreases expression
protein 21081844
D002110 6426 SRSF1
ASF
SF2
SF2p33
SFRS1
SRp30a
serine/arginine-rich splicing factor 1 Caffeine results in decreased expression of SRSF1 mRNA decreases expression
mRNA 11793227
D002110 6770 STAR
STARD1
steroidogenic acute regulatory protein Caffeine results in decreased methylation of STAR promoter decreases methylation
promoter 22100783
D002110 6770 STAR
STARD1
steroidogenic acute regulatory protein Caffeine results in increased expression of STAR mRNA increases expression
mRNA 22100783
D002110 6770 STAR
STARD1
steroidogenic acute regulatory protein Caffeine results in increased expression of STAR protein increases expression
protein 22100783
D002110 55342 STRBP
ILF3L
SPNR
p74
spermatid perinuclear RNA binding protein Caffeine results in decreased expression of STRBP mRNA decreases expression
mRNA 11793227
D002110 7027 TFDP1
DP1
DRTF1
Dp-1
transcription factor Dp-1 Caffeine results in decreased expression of TFDP1 mRNA decreases expression
mRNA 11793227
D002110 10548 TM9SF1
HMP70
MP70
transmembrane 9 superfamily member 1 Caffeine results in decreased expression of TM9SF1 mRNA decreases expression
mRNA 11793227
D002110 9911 TMCC2
HUCEP11
transmembrane and coiled-coil domain family 2 Caffeine results in increased expression of TMCC2 mRNA increases expression
mRNA 18444173
D002110 27346 TMEM97
MAC30
transmembrane protein 97 Caffeine results in decreased expression of TMEM97 mRNA decreases expression
mRNA 11793227
D002110 7292 TNFSF4
CD134L
CD252
GP34
OX-40L
OX4OL
TXGP1
tumor necrosis factor (ligand) superfamily, member 4 Caffeine results in increased expression of TNFSF4 mRNA increases expression
mRNA 18444173
D002110 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Caffeine inhibits the reaction [(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine results in increased expression of and results in increased phosphorylation of TP53 protein] decreases reaction
/ increases expression
/ increases phosphorylation
protein 23274516
D002110 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Caffeine inhibits the reaction [bortezomib results in increased phosphorylation of TP53 protein] decreases reaction
/ increases phosphorylation
protein 12393500
D002110 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Caffeine inhibits the reaction [Capsaicin results in increased phosphorylation of and results in increased activity of TP53 protein] decreases reaction
/ increases activity
/ increases phosphorylation
protein 22226932
D002110 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Caffeine inhibits the reaction [Cytarabine results in increased expression of TP53 protein] decreases reaction
/ increases expression
protein 17977830
D002110 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Caffeine inhibits the reaction [Cytarabine results in increased phosphorylation of TP53 protein] decreases reaction
/ increases phosphorylation
protein 17977830
D002110 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Caffeine inhibits the reaction [decitabine results in increased expression of TP53 protein] decreases reaction
/ increases expression
protein 17977830
D002110 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Caffeine inhibits the reaction [kaempferol results in increased phosphorylation of TP53 protein] decreases reaction
/ increases phosphorylation
protein 19028473
D002110 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Caffeine inhibits the reaction [Nitric Oxide results in increased phosphorylation of TP53 protein] decreases reaction
/ increases phosphorylation
protein 16024610
D002110 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Caffeine inhibits the reaction [oxaliplatin results in increased expression of TP53 protein modified form] decreases reaction
/ increases expression
protein 19735649
D002110 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Caffeine inhibits the reaction [silybin results in increased phosphorylation of TP53 protein] decreases reaction
/ increases phosphorylation
protein 16777994
D002110 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Caffeine inhibits the reaction [spermine nitric oxide complex results in increased phosphorylation of TP53 protein] decreases reaction
/ increases phosphorylation
protein 16024610
D002110 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 Caffeine results in increased phosphorylation of TP53 protein increases phosphorylation
protein 12811820
D002110 7296 TXNRD1
GRIM-12
TR
TR1
TRXR1
TXNR
thioredoxin reductase 1 (EC:1.8.1.9) Caffeine results in decreased expression of TXNRD1 mRNA decreases expression
mRNA 18444173
D002110 54658 UGT1A1
BILIQTL1
GNT1
HUG-BR1
UDPGT
UDPGT_1-1
UGT1
UGT1A
UDP glucuronosyltransferase 1 family, polypeptide A1 (EC:2.4.1.17) Caffeine results in increased expression of UGT1A1 mRNA increases expression
mRNA 18227147
D002110 7385 UQCRC2
MC3DN5
QCR2
UQCR2
ubiquinol-cytochrome c reductase core protein II (EC:1.10.2.2) Caffeine results in decreased expression of UQCRC2 mRNA decreases expression
mRNA 11793227
D002110 7498 XDH
XO
XOR
xanthine dehydrogenase (EC:1.17.1.4 1.17.3.2) XDH protein affects the metabolism of Caffeine affects metabolic processing
protein 14586384
14586387
15199075
15327588
15980104
D002110 10971 YWHAQ
14-3-3
1C5
HS1
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta polypeptide Caffeine inhibits the reaction [CDC25C protein binds to YWHAQ protein] affects binding
/ decreases reaction
protein 11835680
D002110 7587 ZNF37A
KOX21
ZNF37
zinc finger protein 37A Caffeine results in increased expression of ZNF37A mRNA increases expression
mRNA 18444173

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (59)

OMIM preferred title UniProt
#100100 Abdominal muscles, absence of, with urinary tract abnormality and cryptorchidism P20309
#103780 Alcohol dependence P08172
P14416
P31645
#614373 Amyotrophic lateral sclerosis 16, juvenile; als16 Q99720
#300068 Androgen insensitivity syndrome; ais P10275
#312300 Androgen insensitivity, partial; pais P10275
#208900 Ataxia-telangiectasia; at Q13315
#602025 Body mass index quantitative trait locus 9; bmiq9 P41968
#300615 Brunner syndrome P21397
#123400 Creutzfeldt-jakob disease; cjd P04156
#614564 Cutaneous telangiectasia and cancer syndrome, familial; fctcs Q13535
#162800 Cyclic neutropenia P08246
#612522 Diabetes mellitus, insulin-dependent, 22; iddm22 P51681
#607208 Dravet syndrome P35498
#609535 Drug metabolism, poor, cyp2c19-related P33261
#608902 Drug metabolism, poor, cyp2d6-related P10635
#613721 Epileptic encephalopathy, early infantile, 11; eiee11 Q99250
#615363 Estrogen resistance; estrr P03372
#600072 Fatal familial insomnia; ffi P04156
#613659 Gastric cancer P04626
#137215 Gastric cancer, hereditary diffuse; hdgc P04626
#604403 Generalized epilepsy with febrile seizures plus, type 2; gefsp2 P35498
#137440 Gerstmann-straussler disease; gsd P04156
#231095 Ghosal hematodiaphyseal dysplasia; ghdd P24557
#137800 Glioma susceptibility 1; glm1 P04626
#232600 Glycogen storage disease v P11217
#609423 Human immunodeficiency virus type 1, susceptibility to P41597
P51681
#603218 Huntington disease-like 1; hdl1 P04156
#237450 Hyperbilirubinemia, rotor type; hblrr Q9NPD5
Q9Y6L6
#612244 Inflammatory bowel disease 13; ibd13 P08183
#603932 Intervertebral disc disease; idd P14780
#245300 Kuru, susceptibility to P04156
#613688 Long qt syndrome 2; lqt2 Q12809
#211980 Lung cancer P00533
P04626
#608516 Major depressive disorder; mdd P08172
%300852 Mental retardation, x-linked 88; mrx88 P50052
#613073 Metaphyseal anadysplasia 2; mandp2 P14780
#609634 Migraine, familial hemiplegic, 3; fhm3 P35498
#126200 Multiple sclerosis, susceptibility to; ms P08575
#159900 Myoclonic dystonia P14416
#202700 Neutropenia, severe congenital, 1, autosomal dominant; scn1 P08246
#601665 Obesity P32245
#164230 Obsessive-compulsive disorder; ocd P31645
#604715 Orthostatic intolerance P23975
#259730 Osteopetrosis, autosomal recessive 3; optb3 P00918
#167000 Ovarian cancer P04626
#613135 Parkinsonism-dystonia, infantile; pkdys Q01959
#607276 Resting heart rate, variation in P08588
#210600 Seckel syndrome 1; sckl1 Q13535
#607745 Seizures, benign familial infantile, 3; bfis3 Q99250
#608971 Severe combined immunodeficiency, autosomal recessive, t cell-negative, b cell-positive, nk cell-positive P08575
#609620 Short qt syndrome 1; sqt1 Q12809
#313200 Spinal and bulbar muscular atrophy, x-linked 1; smax1 P10275
#606688 Spongiform encephalopathy with neuropsychiatric features P04156
#188570 Thyroid hormone resistance, generalized, autosomal dominant; grth P10828
#274300 Thyroid hormone resistance, generalized, autosomal recessive; grth P10828
#145650 Thyroid hormone resistance, selective pituitary; prth P10828
#190300 Tremor, hereditary essential, 1; etm1 P35462
#610379 West nile virus, susceptibility to P51681
#112100 Yt blood group antigen P22303

KEGG DISEASE (49)

KEGG disease name UniProt
H00016 Oral cancer P00533 (related)
P00533 (marker)
H00017 Esophageal cancer P00533 (related)
P35354 (related)
H00018 Gastric cancer P00533 (related)
P04626 (related)
H00022 Bladder cancer P00533 (related)
P04626 (related)
H00028 Choriocarcinoma P00533 (related)
P03956 (related)
P04626 (related)
H00030 Cervical cancer P00533 (related)
P04626 (related)
H00042 Glioma P00533 (related)
P00533 (marker)
H00055 Laryngeal cancer P00533 (related)
P00533 (marker)
H00241 Combined proximal and distal renal tubular acidosis (RTA type 3) P00918 (related)
H00436 Osteopetrosis P00918 (related)
H00026 Endometrial Cancer P03372 (marker)
P04626 (related)
Q92731 (marker)
H00599 46,XX disorders of sex development (Disorders related to androgen excess) P04150 (related)
H00061 Prion diseases P04156 (related)
H01243 Huntington's disease-like syndrome P04156 (related)
H00019 Pancreatic cancer P04626 (related)
H00027 Ovarian cancer P04626 (related)
H00031 Breast cancer P04626 (related)
P04626 (marker)
H00046 Cholangiocarcinoma P04626 (related)
P35354 (related)
H00093 Combined immunodeficiencies (CIDs) P06239 (related)
H00079 Asthma P07550 (related)
H00100 Neutropenic disorders P08246 (related)
H00091 T-B+Severe combined immunodeficiencies (SCIDs) P08575 (related)
H00036 Osteosarcoma P08684 (marker)
H00024 Prostate cancer P10275 (related)
H00062 Spinal and bulbar muscular atrophy (SBMA) P10275 (related)
H00608 46,XY disorders of sex development (Disorders in androgen synthesis or action) P10275 (related)
H00609 46,XY disorders of sex development (Other) P10275 (related)
H00249 Thyroid hormone resistance syndrome P10828 (related)
H00069 Glycogen storage diseases (GSD) P11217 (related)
H01205 Coumarin resistance P11712 (related)
H00025 Penile cancer P14780 (related)
P35354 (related)
H00479 Metaphyseal dysplasias P14780 (related)
H00548 Brunner syndrome P21397 (related)
H01031 Orthostatic intolerance (OI) P23975 (related)
H00490 Diaphyseal dysplasia with anemia (Ghosal) P24557 (related)
H01171 Poor drug metabolism (PM) P33261 (related)
H00775 Familial or sporadic hemiplegic migraine P35498 (related)
H00783 Febrile seizures P35498 (related)
H00480 Non-syndromic X-linked mental retardation P50052 (related)
H00720 Long QT syndrome Q12809 (related)
H00725 Short QT syndrome Q12809 (related)
H00005 Chronic lymphocytic leukemia (CLL) Q13315 (related)
H00064 Ataxia telangiectasia (AT) Q13315 (related)
H00094 DNA repair defects Q13315 (related)
H00848 Ataxia with ocular apraxia (AOA) Q13315 (related)
H00037 Alveolar rhabdomyosarcoma Q13535 (related)
H00992 Seckel syndrome Q13535 (related)
H00606 Early infantile epileptic encephalopathy Q99250 (related)
H00806 Benign familial neonatal and infantile epilepsies Q99250 (related)

Diseases related to CTD interactions

161 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D000014 D002110 Abnormalities, Drug-Induced marker/mechanism
therapeutic
2467392
3130878
5041373
20864626
D000015 D002110 Abnormalities, Multiple marker/mechanism
20864626
22449533
D000230 D002110 Adenocarcinoma therapeutic
7821872
17145898
D000236 D002110 Adenoma therapeutic
17145898
D017542 D002110 Aneurysm, Ruptured marker/mechanism
12764233
D001008 D002110 Anxiety Disorders marker/mechanism
therapeutic
2036480
2085289
2543990
2607498
2727208
2983630
3358468
3767595
3862156
6505121
7217021
8169187
9588617
9639188
12027348
12825092
14741244
15991002
16184581
16221767
17096081
18305461
20520601
20532872
20599478
D001018 D002110 Aortic Diseases marker/mechanism
12517685
15519028
D001049 D002110 Apnea marker/mechanism
therapeutic
4014092
8274820
11753270
17096081
19052555
D001167 D002110 Arteritis marker/mechanism
8572928
D001281 D002110 Atrial Fibrillation marker/mechanism
6835272
D001282 D002110 Atrial Flutter marker/mechanism
6835272
D054537 D002110 Atrioventricular Block marker/mechanism
10337936
D001289 D002110 Attention Deficit Disorder with Hyperactivity therapeutic
15646857
D001480 D002110 Basal Ganglia Diseases therapeutic
18594798
D001714 D002110 Bipolar Disorder marker/mechanism
1912131
1939933
12676429
D001766 D002110 Blindness marker/mechanism
18945799
D018488 D002110 Bone Demineralization, Pathologic marker/mechanism
19325779
D001929 D002110 Brain Edema marker/mechanism
18945799
D001930 D002110 Brain Injuries therapeutic
12681001
D001943 D002110 Breast Neoplasms marker/mechanism
8823059
D002294 D002110 Carcinoma, Squamous Cell therapeutic
12205293
D002295 D002110 Carcinoma, Transitional Cell marker/mechanism
4638853
D009202 D002110 Cardiomyopathies marker/mechanism
6118996
17953770
D002318 D002110 Cardiovascular Diseases marker/mechanism
16184581
D002375 D002110 Catalepsy therapeutic
9566031
10591873
12907310
18594798
19418355
19654037
D002389 D002110 Catatonia marker/mechanism
4008454
D002543 D002110 Cerebral Hemorrhage marker/mechanism
4024187
6695415
7081793
D023341 D002110 Chills marker/mechanism
3153710
D019970 D002110 Cocaine-Related Disorders marker/mechanism
therapeutic
10639687
10971643
11927167
D003072 D002110 Cognition Disorders therapeutic
20164564
D003110 D002110 Colonic Neoplasms marker/mechanism
12706856
18283038
D003327 D002110 Coronary Disease marker/mechanism
12140349
14747639
15537744
D003329 D002110 Coronary Vasospasm marker/mechanism
19120009
D003645 D002110 Death, Sudden marker/mechanism
7915431
D003866 D002110 Depressive Disorder therapeutic
2085289
D003967 D002110 Diarrhea marker/mechanism
7217021
D004065 D002110 Digestive System Abnormalities marker/mechanism
5041373
D004195 D002110 Disease Models, Animal marker/mechanism
1659560
D004244 D002110 Dizziness marker/mechanism
9639188
D003875 D002110 Drug Eruptions marker/mechanism
11792017
D064420 D002110 Drug-Related Side Effects and Adverse Reactions marker/mechanism
15582667
15764004
16188283
20206647
D004409 D002110 Dyskinesia, Drug-Induced marker/mechanism
8982660
D004487 D002110 Edema marker/mechanism
5041373
22982570
D004715 D002110 Endometriosis marker/mechanism
8823059
D004830 D002110 Epilepsy, Tonic-Clonic marker/mechanism
9639188
16956868
18945799
D005234 D002110 Fatty Liver marker/mechanism
1659560
D005317 D002110 Fetal Growth Retardation marker/mechanism
5041373
8274820
22701600
22959462
D005327 D002110 Fetal Resorption marker/mechanism
5041373
D005334 D002110 Fever marker/mechanism
therapeutic
9296278
15653753
16188283
16889759
D005348 D002110 Fibrocystic Breast Disease marker/mechanism
8823059
D005355 D002110 Fibrosis marker/mechanism
6118996
17994459
D005767 D002110 Gastrointestinal Diseases marker/mechanism
16184581
D005831 D002110 Genital Diseases, Female marker/mechanism
18162812
D005832 D002110 Genital Diseases, Male marker/mechanism
18162812
D005923 D002110 Glomerulosclerosis, Focal Segmental marker/mechanism
10803761
D006029 D002110 Glycosuria therapeutic
17994459
D006130 D002110 Growth Disorders marker/mechanism
1995187
D006212 D002110 Hallucinations marker/mechanism
8767052
D006261 D002110 Headache marker/mechanism
3874838
5468208
9639188
12395591
12780761
12799921
19308315
D006323 D002110 Heart Arrest marker/mechanism
19120009
D006330 D002110 Heart Defects, Congenital marker/mechanism
3719451
D006331 D002110 Heart Diseases marker/mechanism
7915431
D006345 D002110 Heart Septal Defects, Ventricular marker/mechanism
3130878
5041373
D006417 D002110 Hematuria marker/mechanism
2240058
D006470 D002110 Hemorrhage marker/mechanism
5041373
15537744
15653753
D006505 D002110 Hepatitis marker/mechanism
11394713
D006620 D002110 Hip Fractures marker/mechanism
8010338
D006849 D002110 Hydrocephalus marker/mechanism
5041373
D006930 D002110 Hyperalgesia marker/mechanism
therapeutic
12220967
17096081
D006940 D002110 Hyperemia therapeutic
19496111
D006941 D002110 Hyperesthesia marker/mechanism
18162812
D006948 D002110 Hyperkinesis marker/mechanism
therapeutic
2771183
3748325
6677894
10755764
15849377
16470403
20700049
D006965 D002110 Hyperplasia marker/mechanism
6623345
D006973 D002110 Hypertension marker/mechanism
therapeutic
1915209
2272864
2929629
3348458
3414729
6695415
6848713
8607407
10556993
10574509
12140349
14747639
14967827
15696321
D006974 D002110 Hypertension, Malignant marker/mechanism
3020089
D006977 D002110 Hypertension, Renal marker/mechanism
3044993
D020343 D002110 Hypertensive Encephalopathy marker/mechanism
16956868
D007008 D002110 Hypokalemia marker/mechanism
3740695
7909771
10337936
11336759
11512607
20513219
D007022 D002110 Hypotension therapeutic
1898434
D007035 D002110 Hypothermia marker/mechanism
17096081
D007235 D002110 Infant, Premature, Diseases therapeutic
11753270
19052555
D007249 D002110 Inflammation marker/mechanism
therapeutic
17994459
22154906
D007333 D002110 Insulin Resistance therapeutic
10574509
17994459
D007674 D002110 Kidney Diseases marker/mechanism
1783953
4821007
D007680 D002110 Kidney Neoplasms marker/mechanism
2912549
4638853
D007681 D002110 Kidney Papillary Necrosis marker/mechanism
1203171
2240058
4638853
5454357
7412682
D007683 D002110 Kidney Tubular Necrosis, Acute marker/mechanism
10803761
D007859 D002110 Learning Disorders marker/mechanism
therapeutic
3153710
10414431
10682621
15877934
D007905 D002110 Lens Diseases marker/mechanism
3130878
D017114 D002110 Liver Failure, Acute therapeutic
22154906
D008113 D002110 Liver Neoplasms therapeutic
1995187
D008133 D002110 Long QT Syndrome marker/mechanism
11753270
D008175 D002110 Lung Neoplasms therapeutic
17145898
D008206 D002110 Lymphatic Diseases marker/mechanism
3130878
D015674 D002110 Mammary Neoplasms, Animal therapeutic
12706856
D008325 D002110 Mammary Neoplasms, Experimental therapeutic
12706856
D008569 D002110 Memory Disorders marker/mechanism
therapeutic
10414431
15877934
19686781
D008881 D002110 Migraine Disorders marker/mechanism
therapeutic
12220967
12780761
D019964 D002110 Mood Disorders therapeutic
12457274
D019957 D002110 Motor Skills Disorders marker/mechanism
3001551
10682621
D009069 D002110 Movement Disorders marker/mechanism
17096081
D020267 D002110 MPTP Poisoning therapeutic
20230807
D009120 D002110 Muscle Cramp marker/mechanism
17679106
D018908 D002110 Muscle Weakness marker/mechanism
11512607
D009135 D002110 Muscular Diseases marker/mechanism
3001551
20513219
D009139 D002110 Musculoskeletal Abnormalities marker/mechanism
3130878
5041373
D009203 D002110 Myocardial Infarction marker/mechanism
3591779
6118996
19120009
20532872
D017202 D002110 Myocardial Ischemia therapeutic
2795213
D009325 D002110 Nausea marker/mechanism
2983630
3153710
9639188
D009336 D002110 Necrosis marker/mechanism
therapeutic
6850293
15537744
15653753
19325779
19490937
21081844
22154906
D009357 D002110 Neonatal Abstinence Syndrome marker/mechanism
19409249
D009374 D002110 Neoplasms, Experimental therapeutic
17188726
D009395 D002110 Nephritis, Interstitial marker/mechanism
6683361
10803761
D009436 D002110 Neural Tube Defects marker/mechanism
2610378
20641098
22449533
D009765 D002110 Obesity therapeutic
9118819
10574509
D009798 D002110 Ocular Hypertension marker/mechanism
9442454
9673947
D010024 D002110 Osteoporosis marker/mechanism
8010338
8823059
19325779
D010146 D002110 Pain therapeutic
9296278
12240665
15157690
16540851
D016584 D002110 Panic Disorder marker/mechanism
3153710
3767595
8501451
17407170
17427182
17445520
18930777
19698996
D010300 D002110 Parkinson Disease therapeutic
11456310
C537181 D002110 Paroxysmal nonkinesigenic dyskinesia marker/mechanism
6872375
D010911 D002110 Pituitary Neoplasms marker/mechanism
6623345
D010922 D002110 Placenta Diseases marker/mechanism
5041373
D010488 D002110 Polyarteritis Nodosa marker/mechanism
6118996
D011141 D002110 Polyuria marker/mechanism
16184581
D051299 D002110 Post-Dural Puncture Headache therapeutic
12799921
D011230 D002110 Precancerous Conditions marker/mechanism
12824900
D011297 D002110 Prenatal Exposure Delayed Effects marker/mechanism
3001551
3703093
8274820
10682621
19092996
19686781
22959462
D011507 D002110 Proteinuria marker/mechanism
10803761
17994459
D011596 D002110 Psychomotor Disorders marker/mechanism
1335535
D011605 D002110 Psychoses, Substance-Induced marker/mechanism
8767052
19407709
20433105
D012148 D002110 Restless Legs Syndrome marker/mechanism
690085
D012509 D002110 Sarcoma therapeutic
10928167
D012512 D002110 Sarcoma, Ewing therapeutic
15675594
D012559 D002110 Schizophrenia marker/mechanism
690092
D012640 D002110 Seizures marker/mechanism
therapeutic
1329401
1540370
1586430
2388513
2614700
2779359
2821552
3259698
3348458
3575358
3740928
4082203
6308277
6423394
6728873
6848713
6864208
7472302
8575085
9483399
10401785
12956907
14644630
15732443
17439812
18997632
23262392
D012652 D002110 Self Mutilation marker/mechanism
4047283
D012878 D002110 Skin Neoplasms therapeutic
12205293
18179623
D012892 D002110 Sleep Deprivation marker/mechanism
therapeutic
10520732
11903856
D012893 D002110 Sleep Disorders marker/mechanism
164968
1475567
5006984
6851408
7636092
12509552
16184581
19351801
19395429
D007319 D002110 Sleep Initiation and Maintenance Disorders marker/mechanism
3874838
5547885
7217021
9639188
17225163
20532872
D013272 D002110 Stomach Diseases marker/mechanism
8876940
D013274 D002110 Stomach Neoplasms therapeutic
7821872
D020521 D002110 Stroke marker/mechanism
6138529
14747639
D013345 D002110 Subarachnoid Hemorrhage marker/mechanism
4002267
6695415
12764233
D019966 D002110 Substance-Related Disorders marker/mechanism
therapeutic
3153710
6538939
12434259
D013375 D002110 Substance Withdrawal Syndrome marker/mechanism
1576651
2006735
2069491
2372623
2566867
4054205
6497569
7217021
7972294
8147536
8371601
9074914
9695448
9701720
10672630
12676429
12780761
16423144
16470403
18380127
19367462
19630872
20520601
D013575 D002110 Syncope marker/mechanism
10337936
D013610 D002110 Tachycardia marker/mechanism
3348458
5547885
7217021
17953770
D013614 D002110 Tachycardia, Paroxysmal marker/mechanism
6628226
D013617 D002110 Tachycardia, Supraventricular marker/mechanism
6628226
D017180 D002110 Tachycardia, Ventricular marker/mechanism
6835272
10337936
18997632
C572845 D002110 Thyroid cancer, follicular marker/mechanism
12824900
D013981 D002110 Tic Disorders marker/mechanism
9606246
D014202 D002110 Tremor marker/mechanism
1961665
2069491
2983630
3153710
3874838
7217021
8363291
12044659
15696321
16184581
17290375
D014516 D002110 Ureteral Neoplasms marker/mechanism
2912549
D014555 D002110 Urination Disorders marker/mechanism
7217021
D014581 D002110 Urticaria marker/mechanism
11792017
D014693 D002110 Ventricular Fibrillation marker/mechanism
11419773
D018879 D002110 Ventricular Premature Complexes marker/mechanism
18997632
D015431 D002110 Weight Loss marker/mechanism
6623345